US Patent Issued to AstraZeneca on Sept. 22 for "Certain 2,5-diazabicyclo[4.2.0octanes and octahydrofuro[3,4-bpyrazines as GLP-1 receptor modulators" (Swedish Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,741,971, issued on Sept. 22, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Certain 2,5-diazabicyclo[4.2.0octanes and octahydrofuro[3,4-bpyrazines as GLP-1 receptor modulators" was invented by Magnus Polla (Sodertalje, Sweden), Joakim Bergman (Sodertalje, Sweden), Johan Sundell (Sodertalje, Sweden), Jonas Branalt (Sodertalje, Sweden), Ekaterina Ratkova (Sodertalje, Sweden), Johan Kajanus (Sodertalje, Sweden) and Magnus Johansson (Sodertalje, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "There are disclosed certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, and pharmaceutically acceptable salts thereo...